105 related articles for article (PubMed ID: 8182010)
1. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration.
Tsang KW; Roberts P; Read RC; Kees F; Wilson R; Cole PJ
J Antimicrob Chemother; 1994 Feb; 33(2):289-97. PubMed ID: 8182010
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
Burkhardt O; Borner K; Stass H; Beyer G; Allewelt M; Nord CE; Lode H
Scand J Infect Dis; 2002; 34(12):898-903. PubMed ID: 12587622
[TBL] [Abstract][Full Text] [Related]
3. The levels of clarithromycin and its 14-hydroxy metabolite in the lung.
Honeybourne D; Kees F; Andrews JM; Baldwin D; Wise R
Eur Respir J; 1994 Jul; 7(7):1275-80. PubMed ID: 7925906
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.
Kikuchi E; Yamazaki K; Kikuchi J; Hasegawa N; Hashimoto S; Ishizaka A; Nishimura M
Respirology; 2008 Mar; 13(2):221-6. PubMed ID: 18339019
[TBL] [Abstract][Full Text] [Related]
5. Penetration of clarithromycin into lung tissues from patients undergoing lung resection.
Fish DN; Gotfried MH; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1994 Apr; 38(4):876-8. PubMed ID: 8031063
[TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.
Chu S; Wilson DS; Deaton RL; Mackenthun AV; Eason CN; Cavanaugh JH
J Clin Pharmacol; 1993 Aug; 33(8):719-26. PubMed ID: 8408732
[TBL] [Abstract][Full Text] [Related]
7. Clarithromycin pharmacokinetics in healthy young and elderly volunteers.
Chu SY; Wilson DS; Guay DR; Craft C
J Clin Pharmacol; 1992 Nov; 32(11):1045-9. PubMed ID: 1474166
[TBL] [Abstract][Full Text] [Related]
8. Sputum and serum pharmacokinetics of loracarbef (LY163892) in patients with chronic bronchial sepsis.
Hill SL; Bilton D; Johnson MM; Pye A; Mitchell JL; Stockley RA
J Antimicrob Chemother; 1994 Jan; 33(1):129-36. PubMed ID: 8157553
[TBL] [Abstract][Full Text] [Related]
9. Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media.
Sundberg L; Cederberg A
J Antimicrob Chemother; 1994 Feb; 33(2):299-307. PubMed ID: 8182011
[TBL] [Abstract][Full Text] [Related]
10. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.
Kees F; Wellenhofer M; Grobecker H
Infection; 1995; 23(3):168-72. PubMed ID: 7499006
[TBL] [Abstract][Full Text] [Related]
11. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion.
Tagaya E; Tamaoki J; Kondo M; Nagai A
Chest; 2002 Jul; 122(1):213-8. PubMed ID: 12114361
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals.
Womble AY; Giguère S; Lee EA; Vickroy TW
Am J Vet Res; 2006 Oct; 67(10):1681-6. PubMed ID: 17014316
[TBL] [Abstract][Full Text] [Related]
13. Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia.
Offman E; Varin F; Nolan T; Bayliff CD; Bombassaro AM; McCormack DG
Chest; 2000 Apr; 117(4):1090-3. PubMed ID: 10767245
[TBL] [Abstract][Full Text] [Related]
14. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.
Gotfried MH; Danziger LH; Rodvold KA
J Antimicrob Chemother; 2003 Sep; 52(3):450-6. PubMed ID: 12888589
[TBL] [Abstract][Full Text] [Related]
15. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
Sekar VJ; Spinosa-Guzman S; De Paepe E; De Pauw M; Vangeneugden T; Lefebvre E; Hoetelmans RM
J Clin Pharmacol; 2008 Jan; 48(1):60-5. PubMed ID: 18094220
[TBL] [Abstract][Full Text] [Related]
16. [Respiratory pathogen spectrum in pulmonary exacerbation of bronchiectasis in adults and its association with disease severity].
Gao YH; Guan WJ; Zhu YN; Chen RC; Zhang GJ
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Apr; 42(4):254-261. PubMed ID: 30955282
[No Abstract] [Full Text] [Related]
17. Clarithromycin suspension: bioequivalence studies on two different strengths.
Koytchev R; Ozalp Y; Erenmemisoglu A; van der Meer MJ; Alpan RS
Arzneimittelforschung; 2004 Sep; 54(9A):594-9. PubMed ID: 15497666
[TBL] [Abstract][Full Text] [Related]
18. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults.
Guay DR; Craft JC
Pediatr Infect Dis J; 1993 Dec; 12(12 Suppl 3):S106-11. PubMed ID: 8295810
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
[TBL] [Abstract][Full Text] [Related]
20. Sputum sol phase proteins and elastase activity in patients with clinically stable bronchiectasis.
Lloberes P; Montserrat E; Montserrat JM; Picado C
Thorax; 1992 Feb; 47(2):88-92. PubMed ID: 1372451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
